Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$7.06
▲ $0.05 (+0.7%)
Market data updated: 09/20 04:32 PM
Fundamentals updated: 09/19/2026
News analyzed: 09/20/2026
Market Cap
$496.28M
Day Range
$6.70 - $7.15
52-Week Range
$3.25 - $41.80
Beta
—
Next Earnings
04.11.2026
Support
$3.99
Resistance
$8.25
QNRX is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-11.8% (1Y)
Strengths: 9/20 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟡 Mixed
Insiders
🟢 Bullish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Liquidity risk
Current ratio: 3.61
Risk
Biggest negative driver
Daily volatility (ATR)
ATR: 8.9% of price
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
52
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
44
Quality
No data available
Value
50
Momentum
61
Risk
40
Sentiment
62
Fundamental
46
Institutional
100
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has primarily focused on its **sharp intraday stock surge**, with shares rising **24.6% to $6.42** on August 28, 2026, amid broader healthcare sector volatility. The company also announced a **private placement financing of up to $50 million**, signaling strategic funding efforts. While headlines highlight its market activity, no substantive updates on clinical progress or major corporate developments were reported.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Quoin Pharmaceuticals Ltd.. News trend score: 62. Reason: 5 of the last 20 articles are positive, versus 3 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
25
🎯 Conviction (vs. Emotion)
50
Psychology
30
Fundamentals
46
Technical
61
Valuation
50
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+52%
Market Narrative
59
Fundamental Reality
50
Narrative Gap
+9
🧠 StockIQ Psychologist
The market’s euphoric state (88) is unambiguous, driven by relentless momentum and near-universal positive sentiment. The narrative-reality gap (37) suggests traders may be overestimating fundamentals relative to technical extremes. FOMO persists despite muted volume, implying emotional contagion outweighs rational volume signals. The key question: will euphoria sustain despite the stock’s 13.6% proximity to resistance, or will anchoring emerge as a counterbalance?
Updated: 09/06/2026, 05:13 PM
What could change this?
👥 What the crowd believes
"Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome"
"Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million"
"Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 24.6% to $6.42 during Friday’s regular session"
Signal classification confidence: Medium (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
The stark contrast in verdicts for QNRX reflects deep methodological divides between investors prioritizing liquidity, trend-following, and fundamental scrutiny. Walter Bagehot’s near-perfect score highlights the company’s resilience in a credit crunch, aligning with his focus on balance-sheet strength, while Jesse Livermore’s positive trend signal suggests momentum-driven appeal—both contrasting sharply with Howard Marks’ late-cycle caution and Morgan Housel’s volatility warning, which flag behavioral risks. Meanwhile, Benjamin Graham’s lack of valuation data mirrors Philip Fisher’s and Peter Lynch’s limitations, leaving room for speculative interpretations, whereas Thorstein Veblen’s mixed growth-profit signal and Gerald Loeb’s risk flag underscore divergent views on profitability and capital preservation. The efficient-market camp’s skepticism and Charles Mackay’s crowd-delusion warning further polarize the debate, framing QNRX as either a liquidity refuge or a speculative bubble depending on the lens.
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 100
Not enough balance-sheet/valuation data for a real Graham read
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 15%
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟢 100
Not enough valuation data for a real Enterprising-Graham read
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 20%
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 76
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 70
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 62
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 53
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 50
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Peter Lynch
One Up on Wall Street (1989)
🟡 50
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Jack Schwager
Market Wizards (1989)
🟡 43
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 39
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 34
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 33
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 29
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 15
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Based on the last 282 trading days, calculated from real price data. Click an indicator for details and a chart.
🟡 Indicators are mixed — no clear bias (7 bullish · 5 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
—
Net Margin
—
EBITDA Margin
—
ROE
-120.5%
ROA
-77.5%
ROIC
—
EPS
—
Cash
$3.82M
Total Debt
—
Current Ratio
3.61
Debt/Equity
—
אין נתונים היסטוריים זמינים.
אין נתונים היסטוריים זמינים.
אין נתונים היסטוריים זמינים.
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
—
Tangible Book Value per Share (Tangible NAV)
—
Not enough data to compute signals.
Sentiment based on basic keywords (not AI) — 5 positive, 12 neutral, 3 negative out of the last 20 articles.
Benzinga · 10.9.2026
Yahoo · 10.9.2026
GlobeNewswire · 10.9.2026
Yahoo · 8.9.2026
GlobeNewswire · 8.9.2026
Yahoo · 8.9.2026
Pharmaceutical Technology · 8.9.2026
Yahoo · 8.9.2026
GlobeNewswire · 8.9.2026
Benzinga · 8.9.2026
MT Newswires · 28.8.2026
ChartMill · 28.8.2026
Yahoo · 28.8.2026
MT Newswires · 28.8.2026
MT Newswires · 28.8.2026
ChartMill · 28.8.2026
ChartMill · 28.8.2026
Benzinga · 28.8.2026
ChartMill · 28.8.2026
Benzinga · 28.8.2026
Quoin Pharmaceuticals Ltd. (QNRX) currently has a StockIQ AI score of 52/100, rated "Moderate" (a partial score — based on only 6 of 7 categories, some data is currently unavailable). The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
QNRX currently scores 52/100 (Moderate) across the categories we measure (a partial score — based on only 6 of 7 categories, some data is currently unavailable). StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
QNRX's technical score is 61/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Current ratio: 3.61; Price is above the 50-day average; RSI 63.4 — healthy positive momentum.
Based on the real signals StockIQ computed: ATR: 8.9% of price; Calmar: -0.68 (3y annualized return -66.5% / max drawdown 98.3%); Return on equity (ROE): -120.5% (negative).
StockIQ has no recorded dividend payment history for QNRX.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 8 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Carter Denise P. | Open Market Purchase | 31.8.2026 | 10,245 | +10,245 | — |
| Culverwell Anthony James | Open Market Purchase | 31.8.2026 | 6,146 | +6,146 | $4.88 |
| Lawlor Sally Bridget | Open Market Purchase | 31.8.2026 | 5,122 | +5,122 | — |
| Carter Denise P. | Open Market Purchase | 31.8.2026 | 20,490 | +20,490 | $4.88 |
| Culverwell Anthony James | Open Market Purchase | 31.8.2026 | 3,073 | +3,073 | — |
| Lawlor Sally Bridget | Open Market Purchase | 31.8.2026 | 10,244 | +10,244 | $4.88 |
| Myers Michael | Open Market Purchase | 31.8.2026 | 20,490 | +20,490 | $4.88 |
| Myers Michael | Open Market Purchase | 31.8.2026 | 10,245 | +10,245 | — |
| LANGER DENNIS | Grant/Award from Employer | 27.8.2026 | 56,243 | +34,534 | $5.15 |
| Culverwell Anthony James | Grant/Award from Employer | 27.8.2026 | 34,218 | +31,352 | $5.15 |
| Culverwell Anthony James | Grant/Award from Employer | 27.8.2026 | 31,352 | +31,352 | $5.15 |
| LANGER DENNIS | Grant/Award from Employer | 27.8.2026 | 34,534 | +34,534 | $5.15 |
| Myers Michael | Grant/Award from Employer | 4.2.2026 | 318,750 | +318,750 | — |
| Leong Natalie Ee Mun | Grant/Award from Employer | 4.2.2026 | 12,211 | +12,211 | — |
| Carter Denise P. | Grant/Award from Employer | 4.2.2026 | 318,750 | +318,750 | — |
| LANGER DENNIS | Grant/Award from Employer | 4.2.2026 | 21,709 | +21,709 | — |
| Lawlor Sally Bridget | Grant/Award from Employer | 4.2.2026 | 85,250 | +85,250 | — |
| SEMBER MICHAEL T | Grant/Award from Employer | 4.2.2026 | 8,141 | +8,141 | — |
| Culverwell Anthony James | Grant/Award from Employer | 4.2.2026 | 21,709 | +21,709 | — |
| Cooper Joseph Patrick | Grant/Award from Employer | 4.2.2026 | 8,141 | +8,141 | — |
| SEMBER MICHAEL T | Grant/Award from Employer | 4.2.2026 | 8,141 | +8,141 | — |
| LANGER DENNIS | Grant/Award from Employer | 4.2.2026 | 21,709 | +21,709 | — |
| Cooper Joseph Patrick | Grant/Award from Employer | 4.2.2026 | 8,141 | +8,141 | — |
| Leong Natalie Ee Mun | Grant/Award from Employer | 4.2.2026 | 12,211 | +12,211 | — |
| Carter Denise P. | Grant/Award from Employer | 4.2.2026 | 318,750 | +318,750 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
526,654 shares short as of 2026-08-31 · vs. 115,830 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
36.7% of trading volume this week was short selling, vs. 48.6% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology